期刊文献+

乙酰肝素酶及其相关因子mRNA在白血病细胞中的表达 被引量:3

Expression of heparanase and its related factors mRNA in leukemia cells
原文传递
导出
摘要 目的 观察乙酰肝素酶(HPA)及其相关因子mRNA在白血病细胞中的表达,研究白血病细胞表面止血平衡改变.方法 选取白血病患者40例(研究组),缺铁性贫血患者20例(对照组).采用半定量反转录聚合酶链反应(RT-PCR)方法测定受试者骨髓单个核细胞组织因子(TF)、尿激酶型纤溶酶原激活物受体(uPAR)、HPA mRNA的含量.结果 研究组骨髓中单个核细胞TF、uPAR、HPAmRNA的表达与对照组相比均升高(均P<0.05),35例初发白血病患者中急性髓系白血病(AML)组(23例)骨髓中单个核细胞TF、uPAR、HPA mRNA高于慢性粒细胞白血病(CML)组(4例)、慢性淋巴细胞白血病(CLL)组(3例)、急性淋巴细胞白血病(ALL)组(5例)(对照组、AML组、CML组、ALL组、CLL组TF分别为0.66±0.03、2.56±0.37、1.33±0.06、1.93±0.08、1.23±0.07,uPAR分别为0.53士0.02、1.89±0.26、0.92±0.15、1.44±0.01、1.19±0.16,HPA分别为2.37±0.24、1.42±0.13、1.68±0.09、1.54±0.12,均P<0.05).结论 白血病细胞中HPA、TF、uPAR mRNA表达增高;不同类型白血病表达水平不同.提示TF、uPAR、HPA可能影响白血病细胞表面止血平衡,不同类型白血病细胞表面止血平衡改变不同. Objective To explore whether the expression of heparanase (HPA) and other coagulation proteins on blast membrane could determine the hemostatic balance on the surface of leukemia cells.Methods 40 patients with leukemia (study group) and 20 patients with iron deficiency anemia (control group) were analyzed,the levels of TF,uPAR,HPA mRNA were detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR).Results The levels of TF,uPAR,HPA mRNA in study group were higher than those in the control group (P 〈 0.05).The levels of TF,uPAR,HPA mRNA in acute myeloid leukemia (AML) group (23 cases) were significantly higher than those in the acute lymphoblastic leukemia (ALL) (5 cases),chronic myelocytic leukemia (CML) (4 cases),chronic lymphocytic leukemia (CLL) groups (3 cases) (in control,AML,CML,ALL,CLL groups,TF levels were 0.66±0.03,2.56±0.37,1.33±0.06,1.93± 0.08,1.23±0.07,uPAR were 0.53±0.02,1.89±0.26,0.92±0.15,1.44±0.01,1.19±0.16,HPA were 2.37±0.24,1.42±0.13,1.68±0.09,1.54±0.12,respectively,all P 〈 0.05).Conclusions The TF,uPAR and HPA predominate in leukemia cells.The expression of coagulation proteins on blast membrane may determine the hemostatic balance on the surface of leukemia cells,and the hemostatic balance on the blast surface may contribute to thombohemorrhagic syndrome manifestations in leukemic patients.
出处 《白血病.淋巴瘤》 CAS 2015年第6期359-362,共4页 Journal of Leukemia & Lymphoma
基金 内蒙古自然科学基金(2009MS116)
关键词 白血病 乙酰肝素酶 组织因子 尿激酶型纤溶酶原激活物受体 Leukemia Heparanase Tissue factor Urokinase plasminogen activator receptor
作者简介 通信作者:韩轩茂,Email:hanxuanma0123@aliyun.com
  • 相关文献

参考文献17

  • 1Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia [ J ]. Blood (ASH annum meeting abstracts ), 2007, 117 (21) : 151-157.
  • 2Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes ( THS ) in hematologic malignancies [ J ]. Blood ( ASH annual meeting abstracts ), 2007, 117 ( 21 ) : 165-171.
  • 3张冬霞,李志芹,云雁,韩轩茂,贺其图,贾国荣,卢艳,马宏杰,刘学文,白学琴,郭美祥,卓丽霞.白血病细胞表面乙酰肝素酶及其相关蛋白的表达[J].白血病.淋巴瘤,2011,20(12):723-725. 被引量:3
  • 4Nadir Y, Katz T, Sarig G, et al Flemostatie balmaee on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor [ J ]. Haematologica, 2005, 90 ( 11 ) : 1549-1556.
  • 5Hair GA, Padula S, Zeff R, et al. Tissue factor expression in human leukemiccells [ J ]. Leuk Res, 1996, 20 ( 1 ) : 1-11.
  • 6Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid inacute promyelocytic leukemia cells [ J ]. Blood, 1998, 92 ( 1 ) : 143- 151.
  • 7梁江水(综述),董永强,殷桂林(审校).组织因子途径抑制物-2基因与非小细胞肺癌关系的研究进展[J].肿瘤研究与临床,2013,25(10):714-716. 被引量:1
  • 8Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell matrix interactions [ J ]. Trends Biochem Sci, 2000, 25 ( 8 ) : 349-351.
  • 9李阳,刘浩,蒋志文.乙酰肝素酶在肿瘤中的表达及其调控[J].中国药理学通报,2013,29(5):614-617. 被引量:2
  • 10Zhang W, Chan H, Wei L, et al. Overexpression of heparanase in ovarian cancer and its clinical significance [ J ]. Oncol Rep, 2013, 30 ( 5 ) : 2279-2287.

二级参考文献60

  • 1蔡博文,吴波,游潮.SF/HGF受体c-Met在人脑胶质瘤中的表达与肿瘤恶性表型及预后的关系[J].四川医学,2004,25(8):838-839. 被引量:18
  • 2谢燕,王兆钺,张威,戴兰,白霞.白血病细胞系纤溶活性及全反式维甲酸对其影响[J].中华血液学杂志,2006,27(9):588-592. 被引量:6
  • 3KWAAN H C,VICUNA B. Incidence and pathogenesis of thrombosis in hematologic malignancies[J]. Semin Thromb Hemost, 2007,33 : 303- 312.
  • 4JABBOUR E J, ESTEY E, KANTARJIAN H M. Adult acute myeloid leukemia [J]. Mayo Clln Proc, 2006,81 : 247- 260.
  • 5TALLMAN M S, ABUTALIB S A,ALTMAN J K. The double hazard of thrombophilia and bleeding in a cute promyelocytic leukemia[J]. Semin Thromb Hemost, 2007,33 : 330- 338.
  • 6RODEGHIERO F, CASTAMAN G, TOSETTO A, et al. The diseriminant power of bleeding history for the diagnosis of type 1 yon Willebrand disease: an international,multicenter study[J]. J Thromb Haemost,2005,3 : 2619-2626.
  • 7HAJJAR K A,KRISHNAN S. Annexin Ⅱ : a media tor of the plasmin/plasminogen activator system[J]. Trends Cardiovasc Med, 1999,9 : 128 - 138.
  • 8BENE M C, CASTOLDI G, KNAPP W, et al. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders[J]. Leukemia,2004,18:394-400.
  • 9MENELL J S,CESARMAN G M,JACOVINA A T, et al. Annexin Ⅱ and bleeding in acute promyelocytic leukemia[J]. N Engl J Med, 1999,340 : 994- 1004.
  • 10OLWILL S A, MCGLYNNA H, GILMOREA W S, et al. Annexin Ⅱ cell surface and mRNA expression in human acute myeloid leukaemia cell lines[J]. Thromb Res, 2005,115: 109-114.

共引文献5

同被引文献2

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部